Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Shanghai Pharmaceuticals Holding Co Ltd    601607   CNE000000C82

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Shanghai Pharmaceuticals : Advent, Shanghai Pharma have not approached Stada - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2017 | 08:54pm CEST
Logo of the pharmaceutical company Stada Arzneimittel AG is pictured at its headquarters in Bad Vilbel

German drug company Stada Arzneimittel AG has not been approached by Advent International or Shanghai Pharmaceuticals Holding with a counter offer, two sources close to the matter told Reuters on Monday.

Rival buyout firms Bain and Cinven had offered to buy Stada in April, which seemed to end the contest to acquire the generic drug maker, but Bloomberg reported on Monday that Advent and Shanghai Pharmaceuticals are considering making an offer.

Bain and Cinven's offer of 65.28 euros per share and a dividend of 0.72 euros per Stada share was a surprisingly large increase on a previous bid and valued the company at about 5.3 billion euros (4.5 billion pounds).

Bloomberg reported that Advent and Shanghai Pharmaceuticals are discussing a potential bid of about 70 euros a share, citing people familiar with the matter.

However, Reuters' sources said a fresh bid from the duo is unlikely.

"Shanghai Pharmaceuticals is expected to struggle to secure the financing for a possible counterbid," the sources said. "They don’t have much time left to challenge Bain and Cinven."

Advent and Stada declined to comment and Reuters was unable to contact Shanghai Pharmaceuticals outside business hours.

(Additional reporting by Subrat Patnaik in Bengaluru; Editing by David Goodman)

By Alexander Hübner and Pamela Barbaglia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHANGHAI PHARMACEUTICALS H
06/21 STADA ARZNEIMITTEL : Low acceptances leave Stada bid down to the wire
06/07 PROLOGIS : to Build Facilities in Xi'an
05/17 SHANGHAI PHARMACEUTICALS : No Offer Made for Stada Merger
05/17 SHANGHAI PHARMACEUTICALS : Teams Up Bidding for German Peer
05/15 SHANGHAI PHARMACEUTICALS : Advent, Shanghai Pharma have not approached Stada - s..
04/14 Profits show real economy recovery
03/21 SHANGHAI PHARMACEUTICALS : Releases 2016 Annual Results
03/13 SHANGHAI PHARMACEUTICALS : Has No Intention to Buy Stada
03/10 SHANGHAI PHARMACEUTICALS : CVC, Shanghai Pharmaceuticals May Bid for German Peer
2016 SHANGHAI PHARMACEUTICALS : Privatizes Australian Vitaco
More news
Sector news : Retail - Drugs with Grocery
06/22DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens to Settle -- WSJ
06/21DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens Reach Deal to Settle Lawsuit--Upd..
06/21DJWALGREENS BOOTS ALLIANCE : Theranos, Walgreens Reach Deal to Settle Lawsuit
06/20 U.S. Supreme Court again limits where companies can be sued
06/03 Dollar Express sues Dollar Tree for driving it out of business
More sector news : Retail - Drugs with Grocery
News from SeekingAlpha
2015 WEEK IN REVIEW : Hepalink Pharma Buys U.S.-Based CMO Cytovance
2015 WEEK IN REVIEW : Porton Fine Chemicals Buys Dongbang Pharma
Advertisement
Financials ( CNY)
Sales 2017 140 203 M
EBIT 2017 5 017 M
Net income 2017 3 654 M
Finance 2017 362 M
Yield 2017 1,54%
P/E ratio 2017 20,79
P/E ratio 2018 18,27
EV / Sales 2017 0,50x
EV / Sales 2018 0,45x
Capitalization 69 916 M
More Financials
Chart SHANGHAI PHARMACEUTICALS H
Duration : Period :
Shanghai Pharmaceuticals H Technical Analysis Chart | 601607 | CNE000000C82 | 4-Traders
Full-screen chart
Technical analysis trends SHANGHAI PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 24,9  CNY
Spread / Average Target -12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Min Zuo President & Executive Director
Jun Zhou Chairman
You Li Xu Chairman-Supervisory Board
Bo Shen Chief Financial Officer, Director & Vice President
Xin Chen Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHANGHAI PHARMACEUTICA..42.18%10 281
SINOPHARM HOLDING CO L..12.05%12 774
TSURUHA HOLDINGS INC.11.17%5 384
SUNDRUG CO LTD6.06%5 137
COSMOS PHARMACEUTICAL ..7.51%4 133
SUGI HOLDINGS CO.,LTD.9.17%3 427
More Results